OraSure Technologies, Inc.

NasdaqGS:OSUR Stock Report

Market Cap: US$291.7m

OraSure Technologies Valuation

Is OSUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OSUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OSUR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OSUR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OSUR?

Key metric: As OSUR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OSUR. This is calculated by dividing OSUR's market cap by their current earnings.
What is OSUR's PE Ratio?
PE Ratio25.1x
EarningsUS$11.37m
Market CapUS$291.66m

Price to Earnings Ratio vs Peers

How does OSUR's PE Ratio compare to its peers?

The above table shows the PE ratio for OSUR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.6x
UTMD Utah Medical Products
14.6xn/aUS$203.2m
AVNS Avanos Medical
32.8xn/aUS$733.3m
EMBC Embecta
17.4x33.3%US$1.0b
STAA STAAR Surgical
49.7x33.9%US$1.1b
OSUR OraSure Technologies
25.1x-46.8%US$291.7m

Price-To-Earnings vs Peers: OSUR is good value based on its Price-To-Earnings Ratio (25.1x) compared to the peer average (28.6x).

Price to Earnings Ratio vs Industry

How does OSUR's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.1xn/aUS$10.44m
PAVM PAVmed
0.5x-90.0%US$6.79m
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
OSUR 25.1xIndustry Avg. 35.0xNo. of Companies8PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OSUR is good value based on its Price-To-Earnings Ratio (25.1x) compared to the US Medical Equipment industry average (35.3x).

Price to Earnings Ratio vs Fair Ratio

What is OSUR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OSUR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.1x
Fair PE Ratio5.2x

Price-To-Earnings vs Fair Ratio: OSUR is expensive based on its Price-To-Earnings Ratio (25.1x) compared to the estimated Fair Price-To-Earnings Ratio (5.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OSUR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.82
US$5.75
+50.5%
33.4%US$9.00US$4.00n/a4
Feb ’26US$4.02
US$5.75
+43.0%
33.4%US$9.00US$4.00n/a4
Jan ’26US$3.61
US$6.00
+66.2%
28.9%US$9.00US$5.00n/a4
Dec ’25US$3.80
US$6.00
+57.9%
28.9%US$9.00US$5.00n/a4
Nov ’25US$4.17
US$6.00
+43.9%
28.9%US$9.00US$5.00n/a4
Oct ’25US$4.17
US$6.00
+43.9%
28.9%US$9.00US$5.00n/a4
Sep ’25US$4.48
US$6.00
+33.9%
28.9%US$9.00US$5.00n/a4
Aug ’25US$4.51
US$6.13
+35.8%
28.5%US$9.00US$4.50n/a4
Jul ’25US$4.27
US$6.63
+55.2%
20.9%US$9.00US$5.50n/a4
Jun ’25US$4.73
US$6.63
+40.1%
20.9%US$9.00US$5.50n/a4
May ’25US$5.33
US$7.55
+41.7%
11.5%US$9.00US$6.50n/a5
Apr ’25US$6.08
US$7.65
+25.8%
10.0%US$9.00US$7.00n/a5
Mar ’25US$7.27
US$7.65
+5.2%
10.0%US$9.00US$7.00n/a5
Feb ’25US$7.49
US$7.40
-1.2%
22.0%US$9.00US$5.00US$4.025
Jan ’25US$8.20
US$6.40
-22.0%
21.2%US$9.00US$5.00US$3.615
Dec ’24US$7.16
US$6.00
-16.2%
10.5%US$7.00US$5.00US$3.805
Nov ’24US$5.22
US$6.05
+15.9%
9.2%US$7.00US$5.25US$4.175
Oct ’24US$5.93
US$5.95
+0.3%
12.6%US$7.00US$5.00US$4.175
Sep ’24US$6.44
US$5.95
-7.6%
12.6%US$7.00US$5.00US$4.485
Aug ’24US$4.64
US$6.15
+32.5%
15.3%US$7.00US$5.00US$4.515
Jul ’24US$5.01
US$6.95
+38.7%
4.8%US$7.50US$6.50US$4.275
Jun ’24US$5.53
US$6.95
+25.7%
4.8%US$7.50US$6.50US$4.735
May ’24US$6.98
US$6.38
-8.7%
8.5%US$7.00US$5.50US$5.334
Apr ’24US$6.05
US$5.88
-2.9%
11.1%US$7.00US$5.50US$6.084
Mar ’24US$6.15
US$5.88
-4.5%
11.1%US$7.00US$5.50US$7.274
Feb ’24US$5.34
US$5.44
+1.8%
16.7%US$7.00US$4.75US$7.494
Analyst Price Target
Consensus Narrative from 4 Analysts
US$5.75
Fair Value
33.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 01:10
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OraSure Technologies, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charley JonesBarrington Research Associates, Inc.
Karen KoskiBTIG
Mark MassaroCanaccord Genuity